This presentation was originally reviewed on October 26, 2022, and broadcast live online on October 26, 2022, from 12:00 PM – 1:00 PM ET.

Psychodynamic Psychopharmacology is a psychodynamically-informed, patient-centered approach to psychiatric patients that explicitly acknowledges and addresses the central role of meaning and interpersonal factors in pharmacologic treatment. While traditional objective-descriptive psychopharmacology provides guidance about what to prescribe, the techniques of Psychodynamic Psychopharmacology inform prescribers about how to prescribe to maximize outcomes, not only in terms of addressing symptoms, but also in ways that support the patient’s development, increase in the patient’s personal authority, and foster general wellbeing. Join David Mintz, MD, as he discusses the common psychodynamics intereferring with optimal medication outcomes, alliance-promoting behaviors, and treatment-resistance.

Suicide remains a major public health crisis and one of only three of the leading causes of death that are on the rise in the United States affecting those of every age, gender, and ethnic group.  In 2020, suicide was responsible for more ~46,000 deaths, killing on average 13.5 individuals per 100,000 lives. Coupled with this tragedy is the fact that in 2020, 1.2 million Americans made a suicide attempt and more than 12.2 million adults seriously thought about suicide, with more than 3.2 million formulating a plan. There is a myriad of reasons why people take their life with recent estimates that more than half of people who die from suicide do not have a known mental disorder at the time of their death.  Join Cathy Frank, MD, as she defines the epidemiology of suicide, discusses key elements and describes the Henry Ford Zero Suicide Program.

This presentation will address the consistent and emerging mental health disparities faced by Lesbian, Gay, Bisexual, Transgender, and Questioning (LGBTQ+) youth and young adults. Participants will learn the role of technology on the mental health of LGBTQ+ youth and young adults and how to integrate into practice as well as the competencies and conditions for affirmative clinical practice. Many clinicians receive little or no clinical training in supporting the needs of LGBTQ+ Youth in graduate school or beyond, and this unique training offers the specific and emergent strategies to enable competent work with these populations.  Join Shelley L. Craig, Ph.D as she describes the current state of LGBTQ+ youth mental health, and the importance of affirmative practice and strategies.

This presentation was originally reviewed on September 26, 2022, and broadcast live online on September 28, 2022, from 12:oo PM – 1:00 PM ET.

This presentation was originally reviewed on September 13, 2022, and broadcast live online on September 14, 2022, from 12:oo PM – 1:00 PM ET.

The most effective mental health services are a blend of science and art. Evidence-based assessment tools and psychotherapeutic interventions are foundational to achieving patient outcomes, but require clinical skill for selection, application, and adaptation to ensure personalized care. Unfortunately, research has demonstrated that our clinical judgment alone is insufficient to monitor patient progress and adjust treatment accordingly. Measurement-based care (MBC) is the routine use of patient-reported progress measures throughout treatment to guide collaborative decisions about treatment. Join Elizabeth H. Connors, Ph.D, as she provides foundational information about what MBC is and how it can be feasibly integrated into mental health services to optimize patient engagement, goal attainment and treatment outcomes.

Catatonia, a complex psychomotor syndrome, was well know in the early part of the 20th century but faded from discourse in the second half of the 20th century and beyond. Join Rachna Raisinghani, MD, as she provides a brief overview of catatonia and illustrate with real life clinical scenarios how it can be overlooked, encourages learners to have a high index of suspicion, and provides a refresher of the tools for screening, as well as various treatment modalities.

This presentation was originally reviewed on July 27, 2022, and broadcast live online on July 27, 2022, from 12:oo PM – 1:00 PM ET. 

Obsessive-compulsive disorder is common, persistent (in the absence of therapy), and oftentimes disabling.   About 30-40% of patients fail to respond sufficiently to first line treatments of exposure and response prevention (ERP) and serotonin reuptake inhibitors (SRIs).  Adjunctive antipsychotics are the only established second line pharmacological approach. Join Wayne Goodman, MD, as he reviews the literature outcomes with DBS, discusses inclusion/exclusion criteria for implanted devices and surgical procedures, as well as sharing his experience with conducting DBS programming.